Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled “mRNAs Differentially Expressed in Cancer.” The company’s latest innovation, which analyzes a six-mRNA gene combination, has demonstrated a significant increase in sensitivity and specificity for breast cancer detection, compared to previous methods. “We were already doing well, but this is an incredible performance the likes of which we haven’t seen in the genetic breast cancer screening test market,” stated Marvin S. Hausman MD, CSO. Our innovative and non-invasive screening test empowers people to be proactive with their medical care, and potentially detect health issues early on.”

This advancement emerges from extensive research involving over 3,300 cheek cell samples collected from patients across 40 U.S. medical centers, where proprietary machine learning AI technology analyzed more than 12 million combinations of the company’s 48-gene mRNA microarray.

In conjunction with this breakthrough, the company announced plans to rename itself as Revealia™, Inc., pending regulatory approvals and a corresponding ticker symbol change.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc., a biotech and healthcare holding company, is a global leader in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to prevent chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than 50% of deaths worldwide.

For more information please visit: http://www.ludwigent.com. www.revealia.com

SAFE HARBOR

Forward-looking statements in this release are made under the “safe harbor” provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.’s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: LUDG_inc

Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com

SOURCE: Ludwig Enterprise, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago